Clinical Trial

CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

Name: CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency — clinical trial record (NCT07015801)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).

Trial Details

NCT Number	NCT07015801
Lead Sponsor	University of Calgary Collaborators: Alberta Precision Laboratories, Alberta Health services, University of Alberta
Conditions	Cytomegalovirus Viremia, Cytomegalovirus Pneumonia, T-Lymphocyte Immunodeficiency
Enrollment	1 participants
Start Date	2025-04-15
Primary Completion	2027-04 (estimated)
Study Completion	2040-04 (estimated)
Updated on ClinicalTrials.gov	2025-06-11